Latest Financials News

Grand Gulf Energy has resumed trading on the ASX following a pivotal announcement securing new exploration rights alongside a fresh capital raising initiative.

HITIQ has secured an exclusive three-year partnership with Hockey Australia, integrating its PROTEQT™ player safety technology across the sport’s entire national pathway. This deal opens a $20–25 million revenue opportunity and sets a precedent for expansion into other sports.

Atlas Arteria confirms the extension of France’s temporary supplemental tax into 2026 but maintains its 40 cents per share distribution guidance, signalling confidence amid regulatory shifts.

Theta Gold Mines Limited has released a Revised Feasibility Study for its TGME Gold Mine Project in South Africa, projecting robust economics with a 13.1-year mine life and first gold production slated for early 2027.

Aguia Resources has successfully raised $5 million through a well-supported placement to fund key developments in its Colombian gold and Brazilian phosphate projects. The capital injection aims to boost production and strengthen the company's balance sheet.

Matsa Resources has completed processing its second campaign of gold ore from the Devon Pit, producing 23 gold doré bars valued at approximately $25.2 million, with mining for Campaign 3 already underway.

Barton Gold Holdings has kicked off its 2026 drilling campaign at the Tunkillia Gold Project, aiming to secure Ore Reserves, complete a pre-feasibility study, and lodge a Mining Lease application by the end of the year.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Aroa Biosurgery reaffirms strong FY26 guidance, buoyed by favourable US Medicare reimbursement for Symphony and promising trauma study results for Myriad.

Xero Limited has outlined a bold AI strategy and detailed the integration of Melio to accelerate its US market growth, supported by new financial disclosures and a clear path to profitability.

Xero Limited reveals new AI product demonstrations and updates on Melio’s integration, reaffirming ambitious US growth and FY28 revenue targets.